Jobs / United States / Glaxosmithkline LLC
Sr. Director, MASH/ALD Brand Lead & Pipeline
Glaxosmithkline LLC · 🇺🇸 Durham Blackwell Street
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Glaxosmithkline LLC paid sponsored hires in similar roles4 certified filings for “Associate Director – Genomic Technologies” (Molecular and Cellular Biologists) in PA: $134k–$138k, median $136k. Most were filed at wage level IV (50%) — 4 lottery entries, ≈61% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Glaxosmithkline LLC
The US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Glaxosmithkline LLC →
About the role
Business Introduction GSK remains committed to achieving bold commercial ambitions for the future. By 2031, we aim to deliver £40 billion in annual sales, leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patients globally. Our Ahead Together strategy is centered on early intervention to prevent and alter the course of disease, thereby protecting people and supporting healthcare systems. Our diverse portfolio consists of vaccines, specialty medicines, and general medicines. Through continuous innovation and a dedicated focus on scientific and technical excellence, we strive to develop and launch new, groundbreaking treatments that address critical health challenges. Position Summary The role serves as the commercial Brand Lead for MASH/ALD assets and as the primary U.S. commercial authority for the broader Hepatology/Immunology pipeline and portfolio. The role has end-to-end accountability for pipeline strategy from early development through launch readiness and lifecycle management. The role owns and shapes the commercial strategy for MASH/ALD assets as they progress through development toward potential commercialization. It also owns the commercial vision and strategic framework that guide investment decisions, stage-gate recommendations, and commercialization planning for the broader Hepatology/Immunology portfolio, ensuring the U.S. customer and commercial perspective is authoritatively represented across governance forums and global decisions. The role also builds the commercial foundation for other pipeline assets before a dedicated brand team is in place, establishing positioning hypotheses, segmentation frameworks, and go-to-market approaches. For MASH/ALD specifically, this role serves as the commercial and strategic lead for the asset today and is expected to evolve into the full Brand Lead role as the asset advances through key milestones and, if approved, toward launch. The scope of leadership is expected to grow as commercialization planning, launch readiness, and cross-functional team leadership requirements increase. Key Responsibilities: Pipeline Strategy and Commercial Accountability • Serve as the commercial and Brand Lead for MASH/ALD assets, owning and shaping the commercial strategy and leading cross-functional commercial planning and launch-readiness activities as the assets progress through development toward potential commercialization. • Own U.S. pipeline and portfolio strategy for Hepatology/Immunology assets, establishing the commercial vision and prioritization logic that guide investment and launch-readiness decisions from Phase 2 through Local Operating Company (LOC) activation. • Define and deliver, alongside the Medicines Commercialization Team (MCT) and Integrated Brand Commercialization Teams (IBCT), U.S. market analyses, competitive assessments, and commercial assumptions, informed by Medical-owned clinical development plans, health outcomes strategies, and financial valuations for Hepatology/Immunology pipeline assets. • Serve as the single point of accountability for U.S. commercial input at early stage-gates, representing the voice of U.S. HCPs, patients, and payers in development decisions. • Build and own the pre-launch commercial foundation for priority Hepatology/Immunology pipeline assets, including input to the target product profile (TPP), positioning hypotheses, customer segmentation frameworks, and initial value proposition development, ensuring each brand is commercially grounded well in advance of launch. • Deliver stage-gate recommendations to global teams for Phase 2, 2b, and 3 decisions, clearly articulating the U.S. commercial opportunity, risk, and go/no-go rationale. • Establish and e